Q901

Overview

Q901 (CDK7-IN-21) is a selective and potent CDK7 inhibitor with an IC 50 of 10 nM. Q901 disrupts MYC and E2FTOP1 -DPCs and sensitizes tumor to TOP1 inhibitors by suppressing RNAPII transition from initiation to elongation. Q901 can inhibit tumor growth and significantly enhances tumor growth inhibition combined with TOP1 inhibitors. Q901 can be used for the research of cancer , such as colon cancer and lung cancer .

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > Early 2 Factor (E2F) | Products > Signaling Pathways > Topoisomerase

Product Information

• Catalog No.: HY-153278
• CAS No.: 2766124-39-2
• Molecular Formula: C33H36FN9O2
• Molecular Weight: 609.70
• Purity: 99.98%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (4.10 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source